Is Xanax (alprazolam) withdrawal dangerous?

Yes. The FDA prescribing information for XANAX carries a Boxed Warning stating that abrupt discontinuation or rapid dose reduction of alprazolam may precipitate acute withdrawal reactions that can be life-threatening, including seizures. Any discontinuation of alprazolam should be done under medical supervision using a gradual, individualized taper.

What are the most common Xanax withdrawal symptoms?

The FDA label describes discontinuation-emergent symptoms occurring in more than 5% of patients during controlled trials, including heightened sensory perception, impaired concentration, paresthesias (tingling), muscle cramps, muscle twitching, and blurred vision. Insomnia, anxiety rebound, tremor, sweating, nausea, and irritability are also commonly reported clinically.

How long does alprazolam withdrawal last?

Acute withdrawal from short-acting benzodiazepines like alprazolam typically peaks within 1–4 days after the last dose and can continue for several weeks. A subset of patients experience protracted withdrawal symptoms — including anxiety, sleep disruption, and cognitive complaints — for months. Timeline varies by dose, duration of use, individual physiology, and taper design.

Can you die from stopping Xanax cold turkey?

Rapid or abrupt discontinuation of alprazolam has been associated with grand mal seizures, which can be fatal without emergency care. The FDA specifically warns against abrupt cessation for this reason. Anyone taking alprazolam regularly — particularly at higher doses or for longer than a few weeks — should never stop without medical guidance.

How does Sanctuary Tulum's benzodiazepine taper work?

Sanctuary Tulum uses a physician-supervised, individualized taper protocol combined with amino-acid and neuro-restorative IV therapies to support GABA and glutamate rebalancing during dose reduction. Every guest is medically screened, monitored continuously, and tapered on a schedule calibrated to their history, dose, and clinical presentation.

Xanax Alprazolam Withdrawal

Alprazolam — sold under the brand name XANAX — is one of the most widely prescribed benzodiazepines in the United States. It is also one of the most difficult to discontinue. The information below is drawn directly from the FDA-approved prescribing information for XANAX and is provided for educational purposes. It is not medical advice. Never adjust or discontinue a prescribed benzodiazepine without physician supervision.

The FDA Boxed Warning on Alprazolam Discontinuation

The current FDA prescribing information for XANAX includes a Boxed Warning — the strongest warning the FDA can require. Among other risks, the Boxed Warning addresses dependence and withdrawal reactions, stating that continued use of benzodiazepines may lead to clinically significant physical dependence, and that abrupt discontinuation or rapid dosage reduction may precipitate acute withdrawal reactions, which can be life-threatening. The label directs prescribers to use a gradual taper to reduce the risk of these reactions. (Source: FDA prescribing information for XANAX, accessdata.fda.gov.)

The Boxed Warning also flags the risk of withdrawal seizures. According to the label, rapid decrease or abrupt discontinuation of alprazolam has been associated with the emergence of withdrawal reactions including seizures. Seizure risk is elevated in patients taking higher doses, those on alprazolam for extended periods, and those with a personal or family history of seizure disorders.

Discontinuation-Emergent Symptoms Documented in FDA Trials

The XANAX prescribing information reports the discontinuation-emergent symptom profile observed during controlled clinical trials. Symptoms occurring in more than 5% of patients during discontinuation included:

Heightened sensory perception
Impaired concentration
Paresthesias (abnormal skin sensations, often described as tingling or "pins and needles")
Muscle cramps
Muscle twitching
Blurred vision

Clinically, patients also frequently report rebound anxiety, insomnia, tremor, sweating, nausea, gastrointestinal distress, and irritability during dose reduction — some of which overlap with the underlying anxiety disorders for which alprazolam is often prescribed. This overlap is one reason unsupervised tapers fail: distinguishing withdrawal from a relapse of the original condition requires clinical experience.

Why Alprazolam Is Particularly Difficult to Discontinue

Alprazolam has a short elimination half-life relative to other benzodiazepines — approximately 11 hours in healthy adults per the FDA label. Interdose withdrawal ("mini-withdrawals" between doses) can begin well before the next scheduled dose, and this pharmacokinetic profile contributes to both physical dependence and the difficulty of tapering. Long-term use produces adaptive changes at GABA-A receptor complexes; abrupt loss of GABA-ergic tone leaves glutamatergic signaling unopposed, which is the neurobiological basis for withdrawal seizures.

Because of these dynamics, physicians frequently cross-taper patients from alprazolam onto a longer-acting benzodiazepine (such as diazepam or clonazepam) before reducing the total dose — a practice long described in the medical literature and referenced in FDA safety communications about the benzodiazepine class (see the FDA's 2020 class-wide Boxed Warning update).

The DailyMed and NIH Record

For clinicians and patients seeking primary-source documentation, the National Library of Medicine maintains the DailyMed alprazolam label archive, which mirrors the current FDA-approved prescribing information. Older FDA safety communications on benzodiazepine dependence and withdrawal are indexed at fda.gov/drugs/drug-safety-and-availability.

Physician-Supervised Taper at Sanctuary Tulum

Sanctuary Tulum operates a physician-supervised benzodiazepine taper protocol as part of its luxury benzo detox program. Each guest arriving on alprazolam or another benzodiazepine is medically screened, stabilized on an individualized taper schedule, and supported with amino-acid, magnesium, and neuro-restorative IV therapies designed to support GABA-glutamate rebalancing during dose reduction. For a broader clinical overview of benzodiazepine dependence and recovery, see our page on benzo withdrawal.

The Sanctuary Tulum medical team also integrates NAD+ IV therapy, hyperbaric oxygen therapy, and other supportive modalities alongside the taper. For guests whose benzodiazepine use developed alongside other substance dependencies, the taper is delivered within the broader framework of the Pouyan Method. All care is delivered under a federal health license.

References

U.S. Food and Drug Administration. XANAX (alprazolam) tablets, for oral use — Prescribing Information. accessdata.fda.gov (PDF).
U.S. Food and Drug Administration. FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class (2020). fda.gov.
National Library of Medicine, DailyMed. Alprazolam label archive. dailymed.nlm.nih.gov.

Medical disclaimer: This article is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Never stop or change a prescribed benzodiazepine without consulting a qualified physician. If you experience seizure symptoms during benzodiazepine reduction, seek emergency care immediately.

Xanax and alcohol together are a particularly dangerous combination; dual-dependency guests are stepped into our luxury alcohol rehab program during and after benzo stabilization.